Infecciones, hospitalizaciones y mortalidad por COVID-19 en Navarra entre febrero de 2020 y septiembre de 2022

  1. Itziar Casado 1
  2. Manuel García Cenoz 1
  3. Nerea Egüés 1
  4. Cristina Burgui 1
  5. Iván Martínez-Baz 1
  6. Jesús Castilla 1
  1. 1 Instituto de Salud Pública y Laboral de Navarra. Pamplona. España
Revista:
Anales del sistema sanitario de Navarra

ISSN: 1137-6627

Año de publicación: 2023

Volumen: 46

Número: 2

Páginas: 61-70

Tipo: Artículo

DOI: 10.23938/ASSN.1044 DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Anales del sistema sanitario de Navarra

Objetivos de desarrollo sostenible

Resumen

Background. Between February 2020 and September 2022, SARS-CoV-2 has circulated uninterruptedly throughout Spain. This study analyses COVID-19 infections, hospitalizations, and deaths in Navarre.Methods. Enhanced epidemiological surveillance and results of seroepidemiological surveys were used to analyze COVID-19 in-fections, hospitalizations, and deaths, based on the vaccination coverage and other preventive measures applied from February 2020 to September 2022.Results. A total of 295,424 COVID-19 cases were confirmed (45% of the population in Navarre); 8,594 required hospital admis-sion (1.3%), 832 were admitted to intensive care units (1.3‰) and 1,725 died (2.6‰). Over the first wave of the pandemic, there were 1,934 hospitalizations and 529 deaths from confir-med COVID-19 cases over a few weeks; these figures dropped rapidly following lockdown. Until October 2021, SARS-CoV-2 circulation was modulated by non-pharmacological preventive measures. The subsequent relaxation of these measures led to a wide circulation of the omicron variant, increasing the number of cases by three-fold. The high vaccination coverage against COVID-19 introduced decisive changes in the epidemiology of the disease, reducing to less than 2%, 0.1%, and 0.5% the cases requiring hospitalization, intensive care unit admission, or that died, respectively.Conclusions. Initial lockdown and non-pharmacological pre-ventive measures helped control SARS-CoV-2 transmission until vaccination was extended. Vaccination achieved a decisive re-duction of the COVID-19 severity and lethality.

Referencias bibliográficas

  • World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 – 11 March 2020. Geneva: WHO; 2020. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
  • GUAN WJ, NI ZY, HU Y, LIANG WH, OU CQ, HE JX et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382(18): 1708-1720. https://doi.org/10.1056/nejmoa2002032
  • MCALOON C, COLLINS Á, HUNT K, BARBER A, BYRNE AW, BUTLER F et al. Incubation period of COVID-19: a rapid systematic review and meta-analysis of observational research. BMJ Open 2020; 10(8): e039652. https://doi.org/10.1136/bmjopen-2020-039652
  • CASTILLA J, GUEVARA M, MIQUELEIZ A, BAIGORRIA F, IBERO-ESPARZA C, NAVASCUÉS A et al. Risk factors of infection, hospitalization and death from SARS-CoV-2: a population-based cohort study. J Clin Med 2021; 10(12): 2608. https://doi.org/10.3390/jcm10122608
  • Working group for the surveillance and control of COVID-19 in Spain. The first wave of COVID-19 pandemic in Spain: characterization of cases and risk factors for severe outcomes, as at 27 April 2020. Euro Surveill 2020; 25(50): pii=2001431. https://doi.org/10.2807/1560-7917.ES.2020.25.50.2001431
  • Ministerio de Sanidad y Bienestar Social. Procedimiento de actuación frente a casos de infección por el nuevo coronavirus (2019-nCoV). Madrid: 2020.
  • POLLÁN M, PÉREZ-GÓMEZ B, PASTOR-BARRIUSO R, OTEO J, HERNÁN MA, PÉREZ-OLMEDA M et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet 2020; 396(10250): 535-544. https://doi.org/10.1016/S0140-6736(20)31483-5
  • Boletín Oficial del Estado. Declaración de Estado de Alarma en España. https://www.boe.es/buscar/act.php?id=BOE-A-2020-3692
  • Ministerio de Sanidad, Consumo y Bienestar Social. Plan para la transición hacia una nueva normalidad. 2020. https://www.lamoncloa.gob.es/consejodeministros/resumenes/Documents/2020/PlanTransicionNuevaNormalidad.pdf
  • CASTILLA J, MORENO-IRIBAS C, IBERO ESPARZA C, MARTÍNEZ-BAZ I, TROBAJO-SANMARTÍN C, EZPELETA C, GUEVARA M. Primera onda pandémica de COVID-19 en Navarra, febrero - junio 2020. An Sist Sanit Navar 2022; 45(1): e0954. https://doi.org/10.23938/ASSN.0954
  • TROBAJO-SANMARTÍN C, MARTÍNEZ-BAZ I, MIQUELEIZ A, FERNÁNDEZ-HUERTA M, BURGUI C, CASADO I et al. Differences in transmission between SARS-CoV-2 Alpha (B.1.1.7) and Delta (B.1.617.2) variants. Microbiol Spectr 2022; 10(2): e0000822. https://doi.org/10.1128/spectrum.00008-22
  • TROBAJO-SANMARTÍN C, MIQUELEIZ A, GUEVARA M, FERNÁNDEZ-HUERTA M, BURGUI C, CASADO I et al. Comparison of the risk of hospitalization and severe disease among co-circulating Severe Acute Respiratory Syndrome Coronavirus 2 Variants. J Infect Dis 2023; 227(3): 332-338. https://doi.org/10.1093/infdis/jiac385
  • Instituto de Salud Pública y Laboral de Navarra. Pandemia de COVID-19 en Navarra hasta septiembre 2021. Boletín de Salud Pública nº 117. Noviembre 2021. http://www.navarra.es/NR/rdonlyres/AECCD760-AB2A-4841-818A-FA53478FD6DC/478627/BOL1172021.pdf
  • Ministerio de Sanidad. Estrategia de detección precoz, vigilancia y control de COVID-19. https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/COVID19_Estrategia_vigilancia_y_control_e_indicadores.pdf
  • Instituto de Salud Carlos III. Estudio ENE-COVID: Informe final. Estudio Nacional de sero-epidemiología de la infección por SARS-CoV-2 en España. 17 de julio de 2020. Comunidad Foral de Navarra. https://portalcne.isciii.es/enecovid19/informes/ene_covid19_final_15.pdf
  • Departamento de Salud, Gobierno de Navarra. Encuesta de seroprevalencia de anticuerpos frente al SARS-CoV-2 en pacientes de atención primaria de Navarra. http://www.navarra.es/NR/rdonlyres/60EC3E70-CD63-4424-9CED-0382BB32D093/481539/Informe_FINAL_SEROPREVALENCIA_SARSCoV2.pdf
  • Ministerio de Ciencia e Innovación. Vigilancia de la Mortalidad Diaria. https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/MoMo/Paginas/default.aspx
  • CASTILLA J, FRESÁN U, TROBAJO-SANMARTÍN C, GUEVARA M. Altitude and SARS-CoV-2 infection in the first pandemic wave in Spain. Int J Environ Res Public Health 2021; 18: 2578. https://doi.org/10.3390/ijerph18052578
  • MORENO-IRIBAS C, FLORISTÁN Y, INIESTA MARTINEZ I, AICUA EA, GUEVARA ESLAVA M, DELFRADE J. Exceso de mortalidad, mortalidad por COVID-19 y por otras causas en el año 2020 en Navarra, España, An Sist Sanit Navar 2022; 45(3): e1018. https://doi.org/10.23938/ASSN.1018
  • MARTÍNEZ-BAZ I, MIQUELEIZ A, EGÜÉS N, CASADO I, BURGUI C, ECHEVERRÍA A et al. Effect of COVID-19 vaccination on the SARS-CoV-2 transmission among social and household close contacts: A cohort study. J Infect Public Health 2023; 16(3): 410-417. https://doi.org/10.1016/j.jiph.2023.01.017
  • MARTÍNEZ-BAZ I, TROBAJO-SANMARTÍN C, BURGUI C, CASADO I, CASTILLA J. Transmission of SARS-CoV-2 infection and risk factors in a cohort of close contacts. Postgrad Med 2022; 134(2): 230-238. https://doi.org/10.1080/00325481.2022.2037360
  • MARTÍNEZ-BAZ I, MIQUELEIZ A, CASADO I, NAVASCUÉS A, TROBAJO-SANMARTÍN C, BURGUI C et al. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021. Euro Surveill 2021; 26(21): 2100438. https://doi.org/10.2807/1560-7917.ES.2021.26.21.2100438
  • MARTÍNEZ-BAZ I, TROBAJO-SANMARTÍN C, MIQUELEIZ A, GUEVARA M, FERNÁNDEZ-HUERTA M, BURGUI C et al. Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. Euro Surveill 2021; 26(39): 2100894. https://doi.org/10.2807/1560-7917.ES.2021.26.39.2100894
  • MARTÍNEZ-BAZ I, TROBAJO-SANMARTÍN C, MIQUELEIZ A, CASADO I, NAVASCUÉS A, BURGUI C et al. Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022. Euro Surveill 2023 Feb; 28(5): 2200337. https://doi.org/10.2807%2F1560-7917.ES.2023.28.5.2200337
  • CASTILLA J, LECEA Ó, MARTÍN SALAS C, QUÍLEZ D, MIQUELEIZ A, TROBAJO-SANMARTÍN C et al. Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022. Euro Surveill 2022; 27(33): 2200619.https://doi.org/10.2807/1560-7917.ES.2022.27.33.2200619
  • Instituto de Salud Pública y Laboral de Navarra. Vigilancia de enfermedades transmisibles en Navarra en 2022. Boletín de Salud Pública nº 124. Febrero 2023. http://www.navarra.es/NR/rdonlyres/AECCD760-AB2A-4841-818A-FA53478FD6DC/485463/BOL12423EDOS.pdf
  • ALTARAWNEH HN, CHEMAITELLY H, AYOUB HH, TANG P, HASAN MR, YASSINE HM et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. N Engl J Med 2022; 387(1): 21-34. https://www.nejm.org/doi/full/10.1056/NEJMoa2203965
  • World Health Organization. Interim statement on hybrid immunity and increasing population seroprevalence rates. 1 June 2022. https://www.who.int/news/item/01-06-2022-interim-statement-on-hybrid-immunity-and-increasing-population-seroprevalence-rates
  • BOWE B, XIE Y, AL-ALY Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med 2022; 28(11): 2398-2405. https://doi.org/10.1038/s41591-022-02051-3
Fuente de los datos: Dialnet